Detail page

Knowledge Web

Person

Sebastian Halbach

Biologe

Name	Sebastian Halbach
Place	Hamburg (Geburtsort) Deutschland
Gender	männlich
Academic degree	Dr. (Albert-Ludwigs-Universität Freiburg im Breisgau, Fakultät für Biologie) (2016)
Profession	Biologe (characteristic profession)
Related	Molekularbiologie (Studienfach)
Record type	Person
GND-Identifier	1102227625
Record ID	1102227625
Involved in show all Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia Exometabolom analysis of breast cancer cell lines: metabolic signature Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Sebastian Halbach

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo

B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model

BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia

Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia

Exometabolom analysis of breast cancer cell lines: metabolic signature

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells